Health NZ's u-turn on cancer drug Keytruda

A backtrack from Health NZ means some Kiwis will get access to the cancer drug Keytruda before Pharmac begins funding it later this year. Richard Sullivan is the Chief Clinical Officer at Health NZ and joins us to explain their decision. Global sharemarkets have been all over the place recently, with concerns around the state of the US economy seeing some big falls, particularly in the tech sector. And nearly a third of Americans could lose access to one of the most visited websites in the world.